

Index to Volume 9

The index to Volume 9 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in *Clinical*

Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January	1-72
February	73-150
March	151-228
April	229-314
May	315-400
June	401-486

Issue	Pages
July	487-580
August	581-660
September	661-740
October	741-820
November	821-900
December	901-972

Subject Index

A

AIDS, see **Acquired immunodeficiency syndrome**
AIDS-related complex; dideoxyinosine; pancreatitis, risk, NIAID guidelines, 832
Absorption
 carbamazepine; rectal gels, 13
 drugs; interactions, cigarette smoking, 125
 naproxen; interactions, food, sucralfate, 773
Acetaminophen; and diphenhydramine hydrochloride; effects, lack, chills, amphotericin B toxicity, 251
Acquired immunodeficiency syndrome
 antivirals; cytomegalic inclusion disease therapy, review, 613
 clinical studies; research, 153
 dideoxyinosine; pancreatitis, risk, NIAID guidelines, 832
 zidovudine; dosage, reduction, 161; therapy, carcinogenicity, 79
Adenosine
 marketing; FDA approvals, 79
 pharmacology, 271
 tachycardia; paroxysmal supraventricular, therapy, 261
Adnexitis; therapy, 275
Adverse drug reactions report form, 69, 147, 221, 305, 397, 483, 567, 651, 723, 809, 893, 959
Adverse reactions, see **Drugs, adverse reactions**
Advertising Index, 72, 150, 228, 314, 400, 486, 580, 660, 740, 820, 900, 962
Age
 patients; antidepressants, dosage, relation, blood levels, 45
 pediatrics; *Haemophilus b* oligosaccharide conjugate vaccines, immunization, 903
Alcohols, ethyl; vehicles; carbamazepine rectal gels, 13
Aldose reductase inhibitors; pharmacology, 446
Alteplase; comparison, streptokinase; alone and with heparin, myocardial infarction, 329
American Academy of Pediatrics; protocols; *Haemophilus b* oligosaccharide conjugate vaccines, infants, 903
American Pain Society; protocols; acute pain, chronic cancer pain, 601
American Society of Hospital Pharmacists; protocols; anti-infective agents, therapy and prophylaxis, 462; antimicrobial prophylaxis, 423
Amikacin; blood levels; pharmacokinetics, spinal cord injuries, 163
Amikacin sulfate; pharmacokinetics; spinal cord injuries, 163
Amino acids; tryptophan; toxicity, eosinophilia-myalgia syndrome, 250
Aminoglycosides
 amikacin sulfate; pharmacokinetics, spinal cord in-

juries, 163
 blood levels; toxicity, predictions, 788
 gentamicin; blood levels, gravity flow vs. infusion pumps, 777; body distribution, relation, nutrition status, 40; pharmacokinetics, predictions, DrugCalc vs. USC Pack PC programs, 708
 peritonitis; therapy, CAPD, 102
 tobramycin; blood levels, gravity flow vs. infusion pumps, 777; blood levels, minibag vs. syringe pump administration, 541
Aminophylline
 interactions; isoproterenol, methylprednisolone, potentiation, 54
 metabolism; theophylline blood levels, 458
Amitriptyline hydrochloride; dosage; relation, blood levels, 45
Amoxicillin trihydrate; combination, clavulanate potassium; oral, liver abscess therapy, 939
Amphotericin B; toxicity; chills, meperidine prophylaxis, 251
Ampicillin; combination, sulbactam; adnexitis therapy, 275
Ampicillin sodium; combination, sulbactam sodium; i.v., liver abscess therapy, 939
Amrinone lactate; use; review, criteria, quality assurance programs, 882
Analgesics and antipyretics
 acetaminophen; and diphenhydramine, effects, lack, chills, amphotericin B toxicity, 251
 fentanyl citrate; milk and blood levels, labor, 336
 ketorolac tromethamine; pain therapy, 921, 938
 meperidine hydrochloride; patient-controlled analgesia, cesarean section, 92; prophylaxis, chills, amphotericin B toxicity, 251; toxicity, seizures, pediatrics, 337
 morphine sulfate; therapy, pediatrics, 337
 pain; therapy, protocols, American Pain Society, 601
Anesthetics, local
 lidocaine hydrochloride; adverse reactions, hypersensitivity, 338
 procaine hydrochloride; therapy, 338
Angiotensin-converting enzyme inhibitors; hypertension; therapy, diabetes mellitus, 864; therapy, left ventricular heart enlargement, 876
Anistreplase
 marketing; FDA approvals, 78
 pharmacology, 530
Antacids; ulcers; duodenal, therapy, 463
Antiarrhythmic drugs, see **Cardiac drugs**
Anti-infective agents
 prophylaxis; ASHP protocols, 423
 therapy; and prophylaxis, 462
Anti-inflammatory agents

naproxen; availability, interactions, food, sucralfate, 773
 nonsteroidal; pain therapy, protocols, American Pain Society, 601
Antibiotics
 beta lactam; interactions, theophylline, toxicity predictions, methodology, 136
 clavulanate potassium, combination, amoxicillin trihydrate; oral, liver abscess therapy, 939
 monoclonal; biotechnology, research, FDA applications, 408
 otitis media; therapy, 15
 rifampin; toxicity, fever, 57
 sulbactam sodium, combination, ampicillin sodium; i.v., liver abscess therapy, 939
 sulbactam, combination, ampicillin; adnexitis therapy, 275
 vancomycin; blood levels, toxicity, predictions, 788; i.v., DUR criteria, quality assurance programs, 718; peritonitis therapy, CAPD, 102
 vancomycin hydrochloride; pharmacokinetics, pediatrics, ECMO, 711; toxicity, administration routes, 671
Anticoagulants
 heparin; and alteplase or streptokinase, myocardial infarction, 329
 warfarin sodium; interactions, Osmolite, prothrombin time, 93
Anticonvulsants
 carbamazepine; rectal gels, 13
 epilepsy; therapy withdrawal, factors, 781
 phenobarbital sodium; seizures, therapy, pediatrics, 337
 phenytoin; therapy, complications, subarachnoid hemorrhage, 35
Antidepressants
 amitriptyline hydrochloride; dosage, relation, blood levels, 45
 attention deficit disorder with hyperactivity; therapy, pediatrics, review, 632
 clomipramine hydrochloride; pharmacology, review, 165
 fluoxetine hydrochloride; DUR criteria, quality assurance programs, 955
 maprotiline hydrochloride; dosage, relation, blood levels, 45
 nortriptyline hydrochloride; blood and saliva levels, black tongue, 421; dosage, relation, blood levels, 45
Antidiarrhea agents; plantago seed; postcholecystectomy, therapy, 206
Antifungals
 amphotericin B; toxicity, chills, meperidine prophylaxis, 251

- fluconazole; FDA marketing approval, 231
metronidazole; rosacea, topical therapy, 94
- Antihistamines:** diphenhydramine hydrochloride; and acetaminophen, effects, lack, chills, amphotericin B toxicity, 251
- Antineoplastic agents**
bacillus Calmette Guérin live; urinary bladder neoplasms, therapy, marketing approval, 598
breast neoplasms; adjuvant therapy, 667
fludarabine; B-cell chronic lymphocytic leukemia, treatment IND, FDA approvals, 234
flutauracil; combined therapy, colonic and rectal neoplasms, 493
flutauracil and levamisole hydrochloride; colonic neoplasms therapy, 668
ifosfamide; pharmacology, review, 179
levamisole hydrochloride and flutauracil; colonic neoplasms therapy, marketing approval, 668
- Antivirals**
dideoxyinosine; toxicity, pancreatitis, risk, NIAID guidelines, AIDS, 832
foscarnet; cytomegalic inclusion disease therapy, AIDS, review, 613
ganciclovir; cytomegalic inclusion disease therapy, AIDS, review, 613; DUR criteria, quality assurance programs, 644
zidovudine; carcinogenicity, animals, AIDS therapy, 79; dosage reduction, AIDS therapy, 161; early treatment, HIV infections, 248; HIV infections, therapy, pediatrics, 502
- Arrhythmia**
moricizine hydrochloride; therapy, 842
ventricular, therapy, 668
- ASHP Commission on Therapeutics Task Force on Nonsteroidal Prophylaxis:** protocols; anti-infective agents, prophylaxis, 423
- Aspirin**
coronary disease; therapy, 118
mucocutaneous lymph node syndrome; therapy, 755
pain; therapy, protocols, American Pain Society, 601
- Attention deficit disorder with hyperactivity; therapy:** pharmacists' role, 643
- Availability, drugs, see Drugs, availability**
- B**
- Bacillus Calmette Guérin live; marketing:** FDA approval, 598
- Barbiturates:** pseudotumor cerebri; therapy, 762
- BCG live, see Bacillus Calmette Guérin live**
- Betaxolol hydrochloride; marketing:** FDA approvals, 87
- Binding; zinc; mechanism, hepatolenticular degeneration therapy, 951**
- Bioavailability, see Drugs, availability**
- Biologicals; approvals:** FDA, 1989, 159
- Biotechnology; research:** FDA applications, 408
- Bladder neoplasms:** bacillus Calmette Guérin live; urinary, therapy, marketing approval, 598
- Blood; transfusions; and cryoprecipitates, hemorrhage, uremia, therapy, 673**
- Blood levels:**
amikacin; pharmacokinetics, spinal cord injuries, 163
aminoglycosides; gravity flow vs. infusion pumps, 777
amitriptyline; relation, dosage, 45
carbamazepine; rectal gels, 13
desmethylinaprotitine; metabolites, relation, dosage, 45
drugs; toxicity, predictions, 788
fentanyl; and milk levels, 336
gentamicin; predictions, DrugCalc vs. USC Pack PC programs, 708
maprotiline; and metabolites, relation, dosage, 45
naproxen; interactions, food, sucralate, 773
nortriptyline; and saliva levels, black tongue, 421; relation, dosage, 45
quinidine; effects, sample collection tubes, 292
theophylline; aminophylline-isoproterenol-methylprednisolone interactions, potentiation, 54; congestive heart failure, 936; interactions, tetracycline, 546; interactions, toxicity predictions, methodology, 136; predictions, i.v. to oral switch, 421
tobramycin; minibag vs. syringe pump administration, 541
vancomycin hydrochloride; pharmacokinetics, pediatrics, ECMO, 711
- Book Reviews, 146, 226, 313, 657, 736, 898, 961**
Clinical Pharmacy and Therapeutics, Fourth Edition, 226

- Concepts in Immunology and Immunotherapeutics, 657*
Fundamentals of Monitoring Psychoactive Drug Therapy, 736
Gerontokinetics: Pharmacokinetics of Drugs in the Elderly, 313
Handbook of Applied Therapeutics, 227
New Therapeutic Strategies in Hypertension, 146
1989-1990 Pocketbook of Infectious Disease Therapy, 961
Pharmacoepidemiology, 898
Principles of Clinical Toxicology, Second Edition, 659
- Books Received, 72, 228, 314, 400, 580, 660, 740, 820, 900, 962**
- Breast neoplasms; antineoplastic agents; adjuvant therapy, protocols, 667**
- C**
- Calcium antagonists**
hypertension; therapy, diabetes mellitus, 864
ischemia; silent myocardial, therapy, 339
toxicity; Stevens-Johnson syndrome, incidence, 948
- Calculations**
gentamicin; pharmacokinetics, predictions, DrugCalc vs. USC Pack PC programs, 708
globulin immune; dosage, obese patients, 909
- Cancer**
see also **Antineoplastic agents**
analgesics; pain therapy, protocols, American Pain Society, 601
- Cancer drugs, see Antineoplastic agents**
- Carbamazepine; compounding; rectal gels, 13**
- Carcinogenicity; zidovudine; animals, AIDS therapy, 79**
- Cardiac drugs**
adenosine; FDA approvals, 79; paroxysmal supraventricular tachycardia, 261; pharmacology, 271
amrinone lactate; DUR criteria, quality assurance programs, 882
digoxin; blood levels, toxicity, predictions, 788
diltiazem; toxicity, Stevens-Johnson syndrome, 948
moricizine hydrochloride; arrhythmia therapy, 842; FDA marketing approval, 668
nicardipine; therapy, complications, subarachnoid hemorrhage, 35
nifedipine; and beta blockers, silent myocardial ischemia, therapy, 339
nimodipine; therapy, complications, subarachnoid hemorrhage, 35
procainamide; blood levels, toxicity, predictions, 788
quinidine gluconate; blood levels, effects, sample collection tubes, 292
- Catheters; intravenous; extravasation prediction, in-line pressure, infants, 286**
- Ceftriaxone; Lyme disease; therapy, 192**
- Central nervous system stimulants; attention deficit disorder with hyperactivity; therapy, pediatrics, review, 632**
- Cephalosporins**
adnexitis; therapy, 275
ceftriaxone; Lyme disease therapy, 192
peritonitis; therapy, CAPD, 102
- Chlorthalidone; and clonidine; hypertension therapy, left ventricular heart enlargement, 876**
- Cigarettes; smoking; interactions, drug pharmacokinetics, 125**
- Cimetidine; interactions; theophylline, toxicity predictions, methodology, 136**
- Ciprofloxacin**
adnexitis; therapy, 275
concomitant therapy, 671
interactions; theophylline, toxicity predictions, methodology, 136
- Cisapride; gastroparesis; diabetic, therapy, 357**
- Clavulanate potassium; combination, amoxicillin trihydrate; oral, liver abscess therapy, 939**
- Clearance, see Excretion**
- Clinical Pharmacy**
instructions for submitting computer disks with revised manuscripts, 61
procedure for submission of manuscripts to journals published by the American Society of Hospital Pharmacists, 59
- Clinical studies**
acquired immunodeficiency syndrome; research, 153
drugs, investigational; biotechnology products, FDA applications, 408
- Clomipramine hydrochloride; pharmacology; review, 165**
- Clonidine**

- and chlorthalidone; hypertension therapy, left ventricular heart enlargement, 876
patches transdermal; therapy, cyclosporine nephrotoxicity, 49
- Clozapine; schizophrenia; therapy, 682**
- Colitis; olsalazine sodium; ulcerative, therapy, FDA approvals, 908**
- Colonic neoplasms**
flutauracil and levamisole hydrochloride; therapy, 668
levamisole hydrochloride and flutauracil; therapy, 668
therapy; adjuvant, NIH recommendations, 493
- Colony-stimulating factor; graft rejection; bone marrow transplantation, treatment IND, 903**
- Combined therapy**
acquired immunodeficiency syndrome; research, 153
antineoplastic agents; breast neoplasms, protocols, 667
beta blockers and nifedipine; silent myocardial ischemia, 339
chlorthalidone and clonidine; hypertension, left ventricular heart enlargement, 876
clonidine and chlorthalidone; hypertension, left ventricular heart enlargement, 876
flutauracil and leucovorin or levamisole; and radiation, colonic and rectal neoplasms, 493
flutauracil and levamisole hydrochloride; colonic neoplasms, 668
hypotensive agents; hypertension, diabetes mellitus, 864
leucovorin, flutauracil and radiation; colonic and rectal neoplasms, 493
levamisole, flutauracil and radiation; colonic and rectal neoplasms, 493
levamisole hydrochloride and flutauracil; colonic neoplasms, 668
nifedipine and beta blockers; silent myocardial ischemia, 339
radiation, flutauracil and leucovorin or levamisole; colonic and rectal neoplasms, 493
- Comments, 463, 716, 781, 876**
- Complexes**
Haemophilus b oligosaccharide conjugate vaccines and diphtheria CRM₁₉₇ protein; immunization, infants, age, FDA approvals, 903
diphtheria CRM₁₉₇ protein and *Haemophilus b* oligosaccharide conjugate vaccine; immunization, infants, age, FDA approvals, 903
- Compounding; carbamazepine; rectal gels, 13**
- Computers; programs; gentamicin pharmacokinetics, predictions, DrugCalc vs. USC Pack PC, 708**
- Coronary disease; platelet aggregation inhibitors; therapy, 118**
- Correction Notices**
Adenosine in the episodic treatment of paroxysmal supraventricular tachycardia (Apr 1990, CP Continuing Education), 422
Current concepts of silent myocardial ischemia (May 1990, CP Continuing Education), 422
Need for pediatric data in review articles (Mar 1990, Letters), 422
- Costs**
adenosine; paroxysmal supraventricular tachycardia therapy, 79
anistreplase; myocardial infarction therapy, 78
anti-infective agents; therapy and prophylaxis, 462
fluconazole, 231
globulin immune; dosage calculations, obese patients, 909
pegademase bovine; immunologic deficiency syndromes, 408
zidovudine; decreased, dosage, AIDS therapy, 161
- CP Continuing Education, 62, 140, 210, 303, 386, 468, 562, 648, 804, 889, 957**
- Cryoprecipitates; and blood; transfusions, hemorrhage, uremia, therapy, 673**
- Current Literature, 64, 143, 223, 310, 399, 482, 577, 653, 734, 819, 895, 958**
- Cyclosporine; toxicity; kidney, transdermal clonidine therapy, 49**
- Cystic fibrosis**
therapy; and diagnosis, genetics, 716
tobramycin; blood levels, minibag vs. syringe pump administration, 541
- Cytomegalic inclusion disease**
foscarnet; therapy, AIDS, review, 613
ganciclovir; therapy, AIDS, review, 613
- Cytomegalovirus immune globulin; marketing: FDA approval, 493**
- Cytoprotectants**
leucovorin; flutauracil and radiation, colonic and rectal neoplasms, 493
mesna; pharmacology, review, 179

Cytotoxic agents, see Antineoplastic agents

D

Desmethylnaloxone; metabolites; blood levels, relation, dosage, 45

Desmopressin; hemorrhage; uremia, therapy, 673

Devices

infusion pumps; aminoglycoside blood levels, 777; meperidine, patient-controlled analgesia, cesarean section, 92
syringe pumps; vs. minibag administration, tobramycin blood levels, 541

Dextroamphetamine sulfate; attention deficit disorder with hyperactivity; therapy, pediatrics, review, 632

ddl, see Dideoxynosine

Diabetes mellitus

aldose reductase inhibitors; therapy, complications, 446
hypotensive agents; hypertension therapy, 864

Dialysis

hemorrhage; uremia, therapy, 673
peritoneal; continuous ambulatory, peritonitis therapy, 102; continuous ambulatory, vancomycin toxicity, 671

Diarrhea; plantago seed; postcholecystectomy, therapy, 206

Dideoxynosine; toxicity; pancreatitis, risk, NIAID guidelines, AIDS, 832

Digoxin; blood levels; toxicity, predictions, 788

Diltiazem; toxicity; Stevens-Johnson syndrome, 948

Dipalmityl phosphatidylcholine, see Colfosceril palmitate

Diphenhydramine hydrochloride; and acetaminophen; effects, lack, chills, amphotericin B toxicity, 251

Diphtheria CRM₁₁₉ protein; and *Haemophilus b* oligosaccharide conjugate vaccines; immunization, infants, age, FDA approvals, 903

Dipyridamol; coronary disease; therapy, 118

Diuretics; hypertension; therapy, diabetes mellitus, 864; therapy, left ventricular heart enlargement, 876

Domperidone; gastroparesis; diabetic, therapy, 357

Dosage

adenosine; paroxysmal supraventricular tachycardia therapy, 79, 261
amikacin sulfate; spinal cord injuries, 163
aminophylline; interactions, isoproterenol-methylprednisolone, potentiation, blood levels, 54
amitriptyline hydrochloride; relation, blood levels, 45
amrinone lactate; DUR criteria, 882
anistreplase; myocardial infarction therapy, 78, 530
betaxolol hydrochloride; hypertension therapy, FDA approvals, 87
clomipramine hydrochloride; review, 165
fentanyl citrate; milk and blood levels, 336
fluconazole, 231
fludarabine; B-cell chronic lymphocytic leukemia, treatment IND, 234
fluoxetine hydrochloride; DUR criteria, 955
ganciclovir; DUR criteria, 644
gastrointestinal drugs; diabetic gastroparesis therapy, 357
globulin immune, 509; calculations, obese patients, 909; i.v. therapy, 489
hydrochlorothiazide; hypertension therapy, 873
levamisole hydrochloride; colonic neoplasms, 668
lidocaine hydrochloride; adverse reactions, hypersensitivity, 338
maprotiline hydrochloride; relation, blood levels, 45
meperidine hydrochloride; toxicity, seizures, pediatrics, 337
moricizine hydrochloride, 842; arrhythmia therapy, 668
nafarelin acetate, 318
nortriptyline hydrochloride; relation, blood levels, 45
olsalazine sodium; ulcerative colitis therapy, 908
pegademase bovine; immunologic deficiency syndromes, 408
theophylline anhydrous; predictions, i.v. to oral switch, 458
vancomycin hydrochloride; pharmacokinetics, pediatrics, ECMO, 711
vancomycin; i.v., DUR criteria, 718
zidovudine; acquired immunodeficiency syndrome, 161; HIV infections, therapy, pediatrics, 502; high, carcinogenicity, animals, AIDS therapy, 79
zinc sulfate; low, hepatolenticular degeneration therapy, 951

Dosage schedules

Osmolite and warfarin sodium; interactions, prothrombin time effects, 93
ifosfamide; and mesna, neoplasm therapy, 179
iron dextran; effects, plasmapheresis, 419
mesna; and ifosfamide, neoplasm therapy, 179
plantago seed; postcholecystectomy diarrhea, chronic therapy, 206
warfarin sodium and Osmolite; interactions, prothrombin time effects, 93
zidovudine; HIV infections, early treatment, FDA approvals, 248

DPFC, see Colfosceril palmitate

Drug administration

aminoglycosides; blood levels, gravity flow vs. infusion pumps, 777
globulin immune; intravenous, 509
self-medication; meperidine, patient-controlled analgesia, cesarean section, 92

Drug administration routes

carbamazepine; rectal gels, 13
clonidine; transdermal therapy, cyclosporine nephrotoxicity, 49
globulin immune; i.v. therapy, 489
intrathecal; pediatrics, 90
theophylline anhydrous; pharmacokinetics, models, switch from i.v., 458
vancomycin hydrochloride; i.p., toxicity, red-neck syndrome, 671

Drug administration sites; intravenous; inline pressure, catheter extravasation prediction, infants, 286

Drug administration systems; tobramycin; minibag vs. syringe pump administration, blood levels, 541

Drug interactions

adenosine, 271
beta lactams and theophylline; toxicity predictions, methodology, 136
cimetidine and theophylline; toxicity predictions, methodology, 136
ciprofloxacin and theophylline; toxicity predictions, methodology, 36
food and naproxen; availability, 773
isoproterenol hydrochloride, methylprednisolone sodium succinate and theophylline; potentiation, blood levels, 54
ketorolac tromethamine, 921
methylprednisolone sodium succinate, isoproterenol hydrochloride and theophylline; potentiation, blood levels, 54
naproxen and food or sucralate; availability, 773
Osmolite and warfarin sodium; prothrombin time effects, dosage schedules, 93
smoking; cigarettes, effects, pharmacokinetics, 125
sucralate and naproxen; availability, 773
tetracycline hydrochloride and theophylline; blood levels, 546
theophylline and tetracycline hydrochloride; blood levels, 546
theophylline, isoproterenol hydrochloride and methylprednisolone sodium succinate potentiation; blood levels, 54
theophylline; toxicity predictions, methodology, 136
warfarin sodium and Osmolite; prothrombin time effects, dosage schedules, 93

Drug Reaction Alerts, 64, 143, 223, 310, 399, 482, 577, 653, 734, 819, 895, 958

Drugs; new; marketing, FDA approvals, 1989, 159

Drugs, adverse reactions; lidocaine hydrochloride; hypersensitivity, 338

Drugs, availability; naproxen; interactions, food, sucralate, 773

Drugs, body distribution

amikacin; spinal cord injuries, 163
fentanyl; milk and blood levels, 336
gentamicin; predictions, DrugCalc vs. USC Pack PC programs, 708; relation, nutrition status, 40
nortriptyline hydrochloride; blood and saliva levels, black tongue, 421
pharmacokinetics; interactions, cigarette smoking, 125
tobramycin; minibag vs. syringe pump administration, 541
vancomycin hydrochloride; pharmacokinetics, pediatrics, ECMO, 711

Drugs, investigational

investigational new drugs; colony-stimulating factor, treatment protocols, bone marrow transplantation, 903; fludarabine, B-cell chronic lymphocytic leukemia, protocols, 234
new drug applications; biotechnology products, FDA, 408

Drugs, nonprescription; product withdrawal; ingredients, FDA list, 598

Drug use; review; amrinone, criteria, quality assurance

programs, 882; fluoxetine, criteria, quality assurance programs, 955; ganciclovir, criteria, quality assurance programs, 644; globulin immune, criteria, quality assurance programs, 550; vancomycin, criteria, quality assurance programs, 718

Drug withdrawal; anticonvulsants; epilepsy therapy, factors, 781

DUE Criteria, 550, 644, 718, 797, 882, 955

amrinone lactate, 882

ciprofloxacin, 797

fluoxetine hydrochloride, 955

ganciclovir, 644

immune globulin, 550

vancomycin, 718

E

Editorials, 462, 643, 938

Place of ketorolac in pain management, 938

Preventing infectious diseases, 462

Treatment of attention-deficit hyperactivity disorder, 643

Elimination, see Metabolism

Endometriosis; nafarelin acetate; therapy, 318

Enzymes; pectinase bovine; immunologic deficiency syndromes, replacement therapy, 408

Eosinophilia-myalgia syndrome; tryptophan; toxicity, 250

Epilepsy; anticonvulsants; therapy withdrawal, factors, 781

Erythromycins; otitis media; therapy, 15

Estrogens; estrogens conjugated; hemorrhage, uremia, therapy, 673

Estrogens conjugated; hemorrhage; uremia, therapy, 673

Excretion

amikacin; spinal cord injuries, 163
drugs; interactions, cigarette smoking, 125
fentanyl; renal, 336
gentamicin; predictions, DrugCalc vs. USC Pack PC programs, 708
iron dextran; clearance, plasmapheresis, 419
nitrogen; urine urea determinations, modified procedures, 371
theophylline; interactions, toxicity predictions, methodology, 136; urinary, hepatic, congestive heart failure, 936
tobramycin; clearance, minibag vs. syringe pump administration, 541
vancomycin hydrochloride; pharmacokinetics, pediatrics, ECMO, 711

Extracorporeal membrane oxygenation; vancomycin hydrochloride; pharmacokinetics, dosage, pediatrics, 711

F

Fat emulsions; triglycerides; medium and long chains, TPN, 366

Fentanyl citrate; body distribution; milk and blood levels, 336

Fever; rifampin; toxicity, 57

Fluconazole; marketing; FDA approvals, 231

Fludarabine; leukemia; B-cell chronic, treatment IND, FDA approvals, 234

Fluorouracil

and levamisole hydrochloride; colonic neoplasms therapy, 668

leucovorin or levamisole and radiation; colonic and rectal neoplasms, NIH recommendations, 493

Fluoxetine hydrochloride; use; review, criteria, quality assurance programs, 955

Food; interactions; naproxen, availability, 773

Food and Drug Administration (U.S.)

approvals; adenosine, 79; *Haemophilus b* oligosaccharide conjugate vaccines, immunization, infants, age, 903; anistreplase, 78; bacillus Calmette Guérin live, marketing, 598; betaxolol, 87; cytomegalovirus immune globulin marketing, 493; fluconazole, 231; levamisole hydrochloride, 668; moricizine hydrochloride, 668; nafarelin acetate, 318; new drugs, and biologicals, 1989, 159; olsalazine marketing, ulcerative colitis therapy, 908; pectinase bovine, immunologic deficiency syndromes, 408; zidovudine, early treatment, HIV infections, 248
biotechnology; new drug applications, 408
colony-stimulating factor; graft rejection, bone marrow transplantation, treatment IND approval, 903
drugs, nonprescription; ingredients, product with-

drawal, list, 598
fludarabine; B-cell chronic lymphocytic leukemia, treatment IND approvals, 234
zidovudine; dosage reduction, recommendations, AIDS therapy, 161
Foscarnet; cytomegalic inclusion disease; therapy, AIDS, review, 613

G

Ganciclovir
cytomegalic inclusion disease; therapy, AIDS, review, 613
use; review, criteria, quality assurance programs, 644
Gastrointestinal drugs
H₂-antagonists; duodenal ulcer therapy, 463
cimetidine; interactions, theophylline, toxicity predictions, 136
cisapride; diabetic gastroparesis therapy, 357
domperidone; diabetic gastroparesis therapy, 357
metoclopramide; diabetic gastroparesis therapy, 357
sucralfate; interactions, naproxen, availability, 773
Gastroparesis; gastrointestinal drugs; diabetic, therapy, 357
Gels; carbamazepine; rectal, compounding, 13
Genetics; cystic fibrosis; diagnosis, therapy, 716
Genitacin
blood levels; gravity flow vs. infusion pumps, 777
body distribution; relation, nutrition status, 40
pharmacokinetics; predictions, DrugCalc vs. USC Pack PC programs, 708
Globulin immune
dosage; calculations, obese patients, 909
intravenous; DUR, criteria, quality assurance programs, 550
intravenous; therapy, toxicity, 489
mucocutaneous lymph node syndrome; i.v. therapy, 755
pharmacology, 509
Goserelin agonists; nafarelin acetate; endometriosis therapy, FDA marketing approval, 318
Graft rejection; colony-stimulating factor; bone marrow transplantation, treatment IND, 903
Granulocyte macrophage colony-stimulating factor, see **Colony-stimulating factor**
Guidelines, treatment, see **Protocols**

H

HIV infections; zidovudine; early treatment, FDA approvals, 248; therapy, pediatrics, 502
Haemophilus b oligosaccharide conjugate vaccines; and diphtheria CRM₁₉₇ protein; immunization, infants, age, FDA approvals, 903
Haemophilus influenzae; immunization; conjugate vaccines, infants, age, FDA approvals, 903
Half-life
fentanyl; milk and blood levels, 336
gentamicin; predictions, DrugCalc vs. USC Pack PC programs, 708
vancomycin hydrochloride; pharmacokinetics, pediatrics, ECMO, 711
Heart enlargement; therapy; left ventricular, hypertension, 876
Heart failure
amrinone lactate; congestive, DUR criteria, 882
beta blockers; congestive, therapy, 853
theophylline; congestive, effects, metabolism, 936
Heavy metal antagonists; penicillamine; toxicity, hepatolenticular degeneration therapy, 951
Hemorrhage; therapy; uremia, 673
Hemostatics; desmopressin; hemorrhage, uremia, therapy, 673
Heparin; and alteplase or streptokinase; comparisons, myocardial infarction, 329
Hepatolenticular degeneration; zinc sulfate; low dose therapy, mechanism of action, 951
Hydrochlorothiazide; hypertension; dosage, therapy, 873
Hyperalimentation, see **Nutrition**; **parenteral Hypertension**
betaxolol hydrochloride; therapy, FDA marketing approvals, 87
hydrochlorothiazide; dosage, therapy, 873
therapy; diabetes mellitus, 864; left ventricular heart enlargement, 876
Hypotensive agents

betaxolol hydrochloride; FDA marketing approvals, 87
hydrochlorothiazide; dosage, therapy, 873
hypertension; therapy, left ventricular heart enlargement, 876
therapy; diabetes mellitus, 864

I

Iatrogenic diseases, see **Drugs**, **adverse reactions**
Ifosfamide; pharmacology; review, 179
Immunization; *Haemophilus influenzae*; conjugate vaccines, infants, age, FDA approvals, 903
Immunologic deficiency syndromes; pegasedase bovine; therapy, FDA approval, 408
Immunosuppressive agents; cyclosporine; nephrotoxicity, donidine therapy, 49
Immunotherapy
colony-stimulating factor; graft rejection, bone marrow transplantation, treatment IND, 903
cytomegalovirus immune globulin; marketing approval, renal transplantation, 493
globulin immune, 509; dosage calculations, obese patients, 909; i.v., 489; i.v., DUR criteria, quality assurance programs, 550; i.v. mucocutaneous lymph node syndrome, therapy, 755
Infections; therapy; and prophylaxis, 462
Infusion devices, see **Devices**; **infusion pumps**
Injections
aminoglycosides; blood levels, gravity flow vs. infusion pumps, 777
aminophylline; theophylline blood levels, 458
catheters; inline i.v. pressure, extravasation prediction, infants, 286
globulin immune; i.v., therapy, 489
intravenous; pediatrics, 90
Interleukins; biotechnology; research, FDA applications, 408
Intravenous therapy
aminoglycosides; blood levels, gravity flow vs. infusion pumps, 777
tobramycin; blood levels, minibag vs. syringe pump administration, 541
Iron dextran; dosage schedules; effects, plasmapheresis, 419
Iron preparations; iron dextran; dosage, effects, plasmapheresis, 419
Ischemia; therapy; silent myocardial, 339
Isoproterenol hydrochloride; interactions; theophylline, methylprednisolone, potentiation, 54

K

Ketorolac tromethamine; pain; therapy, 938; therapy, review, 921
Kidney failure; dialysis; peritoneal, peritonitis therapy, 102

L

Labeling; zidovudine; decreased dosage, FDA approvals, 161
Labor; fentanyl citrate; milk and blood levels, 336
Lactation; fentanyl; milk levels, 336
Letters, 13, 92, 163, 251, 336, 421, 671, 839, 909
Amikacin pharmacokinetics in a patient with spinal cord injury, 163
Antimicrobial treatment of pelvic inflammatory disease, 839
Consideration in the use of intravenous immune globulin products, 909
Error in *Cancer Chemotherapy Protocols*, 14
Fentanyl excretion in breast milk, 336
Meperidine-associated seizures in a child, 337
Meperidine for prevention of amphotericin B-induced chills, 251
Need for pediatric data in review articles, 164
Patient-controlled analgesia with meperidine after cesarean section, 92
Plasma and salivary nortriptyline concentrations in a patient with black tongue, 421
Rectal administration of carbamazepine gel, 13
Red-neck syndrome associated with intraperitoneal vancomycin, 671
Reversal of Osmolite-warfarin interaction by changing warfarin administration time, 93
Supersensitivity to subcutaneous lidocaine, 338
Leucovorin; fluorouracil and radiation; colonic and

rectal neoplasms, NIH recommendations, 493
Leukemia; fludarabine; B-cell chronic, treatment IND, FDA approvals, 234
Levamisole; fluorouracil and radiation; colonic and rectal neoplasms, NIH recommendations, 493
Levamisole hydrochloride; marketing; FDA approvals, colonic neoplasms, 668
Lidocaine hydrochloride; adverse reactions; supersensitivity, 338
Liver abscess
amoxicillin trihydrate, combination, clavulanate potassium; oral therapy, 939
ampicillin sodium, combination, sulbactam sodium; i.v. therapy, 939
L-Tryptophan, see **Tryptophan**
Lyme disease; therapy, 192

M

Maprotiline hydrochloride; dosage; relation, blood levels, 45
Marketing
adenosine; FDA approvals, 79
anistreplase; FDA approvals, 78
bacillus Calmette Guérin live; FDA approval, 598
betaxolol hydrochloride; FDA approvals, 87
cytomegalovirus immune globulin; FDA approval, 493
fluconazole; FDA approvals, 231
levamisole hydrochloride; FDA approvals, 668
moricizine hydrochloride; FDA approvals, 668
nafarelin acetate; FDA approvals, 318
new drugs; and biologicals, FDA approvals, 1989, 159
olsalazine sodium; FDA approvals, ulcerative colitis therapy, 908
Mechanism of action
beta blockers; congestive heart failure therapy, 853
gastrointestinal drugs; diabetic gastroparesis therapy, 357
genetics; cystic fibrosis, diagnosis, therapy, 716
globulin immune; i.v. therapy, 489
metronidazole; topical, rosacea therapy, 94
zinc sulfate; hepatolenticular degeneration therapy, 951
Meperidine hydrochloride
patient-controlled analgesia; cesarean section, 92
therapy; chills, prophylaxis, amphotericin B toxicity, 251
toxicity; seizures, pediatrics, 337
Mesna; pharmacology; review, 179
Metabolism
antidepressants; desmethyl metabolites, blood levels, 45
drugs; interactions, cigarette smoking, 125
meperidine hydrochloride; normeperidine metabolites, toxicity, pediatrics, 337
moricizine hydrochloride, 668
theophylline; congestive heart failure, 936
Methodology
clinical trials; AIDS, research, 153
gentamicin; pharmacokinetics, predictions, DrugCalc vs. USC Pack PC programs, 708
injections; inline i.v. pressure, extravasation prediction, infants, 286
theophylline; blood levels, predictions, i.v. to oral switch, 458
toxicity; predictions, drug blood levels, 788; predictions, drug interactions, 136
Methyldopa; and diuretics; hypertension therapy, left ventricular heart enlargement, 876
Methylhydroxyethylcellulose; vehicles; carbamazepine rectal gel, 13
Methylphenidate hydrochloride; attention deficit disorder with hyperactivity; therapy, pediatrics, review, 632
Methylprednisolone sodium succinate; interactions; theophylline-isoproterenol, potentiation, 54
3-Methylxanthine; metabolites; theophylline, congestive heart failure, 936
Metoclopramide; gastroparesis; diabetic, therapy, 357
Metronidazole; rosacea; topical therapy, 94
Minerals
diet; RDA changes, 11
zinc sulfate; low dose, hepatolenticular degeneration therapy, 951
Misoprostol; ulcers; duodenal, therapy, 463
Models; theophylline anhydrous; pharmacokinetics, switch from i.v., 458
Monoamine oxidase inhibitors; attention deficit disorder with hyperactivity; therapy, pediatrics, review, 632

Moricizine hydrochloride
marketing; FDA approvals, arrhythmia therapy, 668
pharmacology, 842
Morphine sulfate; therapy; pain, pediatrics, 337
Mucocutaneous lymph node syndrome; therapy, 755
Myocardial infarction
alteplase, comparison, streptokinase; alone and
with heparin, therapy, 329
anistreplase; therapy, 78, 530
heparin and alteplase or streptokinase; therapy, 329
streptokinase, comparison, alteplase; alone and
with heparin, therapy, 329

N

Nafarelin acetate; marketing; FDA approvals, 318
Naproxen; interactions; sulcralfate, food, availability,
773
National Academy of Sciences; National Research
Council; Food and Nutrition Board, RDA changes,
11
**National Institute of Allergy and Infectious Dis-
eases**; protocols; dideoxynucleoside therapy, pancreati-
tis risk, AIDS, 832
National Institutes of Health; protocols; breast neo-
plasms, adjuvant therapy, 667
Neoplasms
ifosfamide and mesna; therapy, 179
mesna and ifosfamide; therapy, 179
News, 3, 78, 153, 231, 318, 403, 489, 583, 667, 743, 823,
903
Adenosine approved for treatment of paroxysmal
supraventricular tachycardia, 79
American Academy of Pediatrics issues recommen-
dations on dexamethasone therapy for bacterial
meningitis, 752
Anistreplase introduced for therapy of acute myo-
cardial infarction, 78
Antithrombotic therapy prevents strokes in patients
with atrial fibrillation, study finds, 333
Atenolol receives post-myocardial-infarction indica-
tion; i.v. formulation marketed, 12
BCG product released for therapy of urinary blad-
der cancer, 598
Caution urged in interpretation of zidovudine
carcinogenicity study results, 79
CDC issues guidelines for protection against viral
hepatitis, 670
CDC updates guidelines for influenza control, 823
CDC updates recommendations on treatment of
sexually transmitted diseases, 3
Conference examines study-design issues in AIDS
research, 153
Consensus conference evaluates key issues concern-
ing use of intravenous immune globulin, 489
Consensus panel considers adjuvant therapy for
colon and rectal cancer, identifies levamisole-
fluorouracil as standard in colon cancer, 493
Enzyme replacement product approved for rare
immunodeficiency disorder, 408
Expanded use of granulocyte-macrophage colony-
stimulating factor approved by FDA, 903
FDA advisory committee recommends earlier use of
zidovudine, 248
FDA advisory committee recommends easing re-
strictions on use of oral contraceptives by older
women, 12
FDA approves marketing of cytomegalovirus im-
mune globulin, 493
FDA approves nafarelin for treatment of endometri-
osis, 318
FDA approves 23 new drugs for marketing in 1989,
159
FDA approves treatment IND protocol for use of
zidovudine in children, 12
FDA proposes banning 258 nonprescription drug
ingredients, 598
Guidelines for malaria prevention revised to include
primary role for mefloquine, 599
Increasing number of biotechnology products near
marketing, PMA survey shows, 408
Indications for zidovudine expanded to include use
in children, 502
Intrathecal baclofen therapy granted treatment IND
status, 408
Levamisole approved for use in adjuvant regimen
for colon cancer, 668
Marketing of synthetic surfactant approved by
FDA, 753
Methylprednisolone improves neurologic function
after spinal-cord injury, study shows, 502

More cases of eosinophilia-myalgia syndrome
linked to L-tryptophan use, 250
New Class I antiarrhythmic, moricizine, approved
by FDA, 668
New Recommended Daily Allowances set for nutri-
ents, 11
News Briefs, 12, 88, 161, 250, 334, 408, 506, 599, 670,
753, 838, 908
NIAID updates dideoxynucleoside toxicity profile, sug-
gests ways to reduce risk of pancreatitis, 832
Olsalazine approved for use in ulcerative colitis, 908
Oral betaxolol approved for once-daily therapy of
hypertension, 87
Panel reviews therapy for early breast cancer; ex-
plicit advice on adjuvant therapy lacking, 667
Postexposure use of zidovudine by health-care
workers examined in Public Health Service state-
ment, 403
Preceptor applications due for Foundation Fellow-
ships Program, 502
Public Health Service proposes policy for parallel-
track access program, 583
Quazepam marketed for treatment of insomnia, 753
Recommendations for zidovudine dosage reduction
reflected in revised product labeling, 161
Recommended age for use of *Haemophilus b* oligo-
saccharide conjugate vaccine lowered to two
months, 903
Report on nutritional support in AIDS offered for
public comment, 250
Report on zidovudine use in asymptomatic human
immunodeficiency virus infection published, 406
Scientific perspectives from the Sixth International
Conference on AIDS, 743
Streptokinase-alteplase study fuels ongoing contro-
versy over thrombolytic selection, 329
Studies reach opposite conclusions regarding role of
vitamins in preventing neural-tube defects, 87
Survey suggests Alzheimer's disease is common
problem among elderly Americans, 87
Systemic antifungal agent fluconazole receives mar-
keting approval, 231
Treatment IND protocol expands access to fludarabi-
ne, 234
Upcoming Specialty Meetings, 12, 88, 161, 250, 335,
418, 506, 599, 670, 754, 838, 908
World Health Organization issues recommenda-
tions for prevention, diagnosis, and treatment of
strokes, 330
Nicardipine; therapy; complications, subarachnoid
hemorrhage, 35
Nicotine; smoking; cigarettes, drug interactions, 125
Nifedipine; alone and with beta blockers; silent myo-
cardial ischemia, therapy, 339
Nimodipine; therapy; complications, subarachnoid
hemorrhage, 35
Nitrates; ischemia; silent myocardial, therapy, 339
Nitrogen; excretion; urine urea determinations, modi-
fied procedures, 371
Normeperidine; metabolites; meperidine, toxicity, sei-
zures, pediatrics, 337
Northriptyline hydrochloride
body distribution; blood and saliva levels, black
tongue, 421
dosage; relation, blood levels, 45
Nutrition
diet; RDA changes, 11
enteral; Osmolite, interactions, warfarin, dosage
schedules, 93
parenteral; fat emulsions, medium- and long-chain
triglycerides, 366
Nutrition disorders; effects; gentamicin body distribu-
tion, 40

O

Obesity; globulin immune; dosage calculations, 909
Obsessive-compulsive disorder; clomipramine hy-
drochloride; therapy, review, 165
Olsalazine sodium; colitis; ulcerative, therapy, FDA
approval, 908
Omeprazole; ulcers; duodenal, therapy, 463
Opiates; pain; therapy, protocols, American Pain Soci-
ety, 601
Organizations
American Academy of Pediatrics; protocols, *Haemo-
philus b* oligosaccharide conjugate vaccines, in-
fants, 903
National Institute of Allergy and Infectious Dis-
eases; protocols, dideoxynucleoside therapy, pan-
creatitis risk, AIDS, 832

Osmolite; interactions; warfarin, prothrombin time
effects, dosage schedules, 93
Otitis media; therapy, 15

P

Pain
clomipramine hydrochloride; chronic, therapy, re-
view, 165
ketorolac tromethamine; postoperative, therapy,
921; therapy, 938
meperidine hydrochloride; patient-controlled anal-
gesia, cesarean section, 92
Pancreatitis; dideoxynucleoside; toxicity, risk, NIAID
guidelines, AIDS, 832
Parenterals, see **Injections**
Patches transdermal; clonidine; therapy, cyclosporine
nephrotoxicity, 49
Patient-controlled analgesia; meperidine hydrochlo-
ride; cesarean section, 92
Pediatrics
attention deficit disorder with hyperactivity; ther-
apy, pharmacists' role, 643
drug administration routes; intraosseous, 90
ganciclovir; DUR criteria, quality assurance pro-
grams, 644
Haemophilus b oligosaccharide conjugate vaccines;
infants, immunization, age, FDA approvals, 903
injections; inline i.v. pressure, catheter extravasation
prediction, infants, 286
meperidine hydrochloride; toxicity, seizures, 337
psychotherapeutic agents; attention deficit disorder
therapy, review, 632
vancomycin hydrochloride; pharmacokinetics, in-
fants, ECMO, 711
zidovudine; HIV infections, therapy, 502
PEG-ADA, see **Pegademase bovine**
Pegademase bovine; immunologic deficiency syn-
dromes; therapy, FDA approval, 408
Femoline; attention deficit disorder with hyperactiv-
ity; therapy, pediatrics, review, 632
Penicillamine; toxicity; side effects, hepatolenticular
degeneration therapy, 951
Penicillin
adnexitis; therapy, 275
Lyme disease; therapy, 192
Penicillins
amoxicillin trihydrate, combination, clavulanate
potassium; oral, liver abscess therapy, 939
ampicillin, combination, sulbactam; adnexitis ther-
apy, 275
ampicillin sodium, combination, sulbactam sodium;
i.v., liver abscess therapy, 939
otitis media; therapy, 15
penicillin; adnexitis therapy, 275; Lyme disease ther-
apy, 192
Pharmacists; role; attention deficit disorder with hy-
peractivity, therapy, 643
Pharmacokinetics
adenosine, 79; paroxysmal supraventricular
tachycardia therapy, 261
aldose reductase inhibitors, 446
amikacin sulfate; spinal cord injuries, 163
amitriptyline hydrochloride; dosage, relation, blood
levels, 45
anistreplase, 530, 78
betaxolol hydrochloride, 87
clomipramine hydrochloride; review, 165
drugs; interactions, cigarette smoking, 125; toxicity
predictions, methodology, 136
fluconazole, 231
gastrointestinal drugs; diabetic gastroparesis ther-
apy, 357
gentamicin; predictions, DrugCalc vs. USC Pack PC
programs, 708
globulin immune, 509
ifosfamide; review, 179
iron dextran; plasmapheresis, dosage schedules,
419
ketorolac tromethamine, 921
maprotiline hydrochloride; dosage, relation, blood
levels, 45
mesna; review, 179
metronidazole; topical, rosacea therapy, 94
moricizine hydrochloride, 842; arrhythmia therapy,
668
nafarelin acetate, 318
naproxen; interactions, food, sulcralfate, 773
northriptyline hydrochloride; dosage, relation, blood
levels, 45
olsalazine sodium; ulcerative colitis therapy, 908
pegademase bovine, 408

theophylline; congestive heart failure, 936
 theophylline anhydrous; models, switch from i.v., 458
 tobramycin; blood levels, minibag vs. syringe pump administration, 541
 vancomycin hydrochloride; dosage, pediatrics, ECMO, 711
Pharmacy, institutional, hospital; quality assurance; ganciclovir, DUR criteria, 644; programs, amrinone, DUR criteria, 882; programs, fluoxetine, DUR criteria, 955; programs, i.v. globulin immune, DUR criteria, 550; programs, i.v. vancomycin, DUR criteria, 718
Phenobarbital sodium; seizures; therapy, meperidine toxicity, pediatrics, 337
Phenytoin; therapy; complications, subarachnoid hemorrhage, 35
Plantago seed; diarrhea; postcholecystectomy, therapy, 206
Plasmapheresis; effects; iron dextran clearance, dosage schedules, 419
Platelet aggregation inhibitors
 aspirin; mucocutaneous lymph node syndrome, therapy, 755
 coronary disease; therapy, 118
Pressure; catheters; inline, extravasation prediction, lack, infants, 286
Procainamide; blood levels; toxicity, predictions, 788
Procaine hydrochloride; anesthetics, local; therapy, 338
Product development; biotechnology; research, FDA applications, 408
Product withdrawal; drugs, nonprescription; ingredients, FDA list, 598
Prostacyclin; coronary disease; therapy, 118
Proteins; diet; RDA changes, 11
Protocols
 acquired immunodeficiency syndrome; clinical trials, 153
 American Academy of Pediatrics; *Haemophilus b* oligosaccharide conjugate vaccines, infants, 903
 American Society of Hospital Pharmacists; antimicrobial prophylaxis, 423
 amrinone lactate; DUR criteria, 882
 analgesics; pain therapy, American Pain Society, 601
 anti-infective agents; therapy and prophylaxis, 462
 antineoplastic agents; adjuvant therapy, breast neoplasms, 667
 colonic neoplasms; adjuvant therapy, NIH recommendations, 493
 colony-stimulating factor; graft rejection, bone marrow transplantation, treatment IND, 903
 fludarabine; B-cell chronic lymphocytic leukemia, treatment IND, 234
 fluoxetine hydrochloride; DUR criteria, 955
 ganciclovir; DUR criteria, 644
 globulin immune; i.v. DUR criteria, 550
 National Institute of Allergy and Infectious Diseases; dideoxynosine therapy, pancreatitis risk, AIDS, 832
 rectal neoplasms; adjuvant therapy, NIH recommendations, 493
 vancomycin; i.v., DUR criteria, 718; i.v., DUR criteria, quality assurance programs, 718
 zidovudine; early treatment, HIV infections, 248
Pseudotumor cerebri; therapy, 762
Psychotherapeutic agents; attention deficit disorder with hyperactivity; therapy, pediatrics, review, 632
Psychotic disorders; clomipramine hydrochloride; therapy, review, 165
Psyllium hydrophilic mucilloid, see Plantago seed
Purpura; iron dextran; thrombocytopenic, dosage, effects, plasmapheresis, 419

Q

Quality assurance; hospital pharmacy; ganciclovir, DUR criteria, 644; programs, amrinone, DUR criteria, 882; programs, fluoxetine, DUR criteria, 955; programs, i.v. globulin immune, DUR criteria, 550; programs, i.v. vancomycin, DUR criteria, 718
Quinidine; blood levels; effects, sample collection tubes, 292
Quinidine gluconate; blood levels; effects, sample collection tubes, 292
Quinolones; ciprofloxacin; adnexitis therapy, 275; interactions, theophylline, toxicity predictions, 136

R

Radiation; fluorouracil and leucovorin or levamisole; colonic and rectal neoplasms, NIH recommendations, 493
Radioprotective agents; levamisole; fluorouracil and radiation, colonic and rectal neoplasms, 493
Rational therapy
 anti-infective agents, 462
 globulin immune; i.v., 489
 polypharmacy; aminophylline-isoproterenol-methylprednisolone interactions, potentiation, 54
 zidovudine; carcinogenicity, animals, AIDS, 79
Rectal neoplasms; therapy; adjuvant, NIH recommendations, 493
Regulations
 bacillus Calmette Guérin live; FDA marketing approval, 598
 Food and Drug Administration; nonprescription ingredients, withdrawal, 598
Replacement solutions; therapy; complications, subarachnoid hemorrhage, 35
Research
 acquired immunodeficiency syndrome; clinical studies, 153
 biotechnology; and FDA applications, 408
 globulin immune; i.v. therapy, 489
Respiratory smooth-muscle relaxants
 aminophylline; interactions, isoproterenol-methylprednisolone, potentiation, blood levels, 54
 theophylline; blood levels, toxicity, predictions, 788; interactions, tetracycline, 546; interactions, toxicity predictions, methodology, 136; metabolism, congestive heart failure, 936
 theophylline anhydrous; pharmacokinetics, models, switch from i.v., 458
Rifampin; toxicity; fever, 57
Rosacea; metronidazole; topical therapy, 94

S

Saliva levels; nortriptyline; and blood levels, black tongue, 421
Schizophrenia; clozapine; therapy, 682
Seizures
 carbamazepine; therapy, rectal gels, 13
 meperidine hydrochloride; toxicity, pediatrics, 337
Smoking; cigarettes; interactions, drug pharmacokinetics, 125
Spinal cord injuries; amikacin sulfate; pharmacokinetics, 163
Steroids, cortico-
 methylprednisolone sodium succinate; interactions, isoproterenol-theophylline, potentiation, blood levels, 54
 mucocutaneous lymph node syndrome; therapy, 75
Stevens-Johnson syndrome; diltiazem; toxicity, 948
Streptokinase; comparison, alteplase; alone and with heparin, myocardial infarction, 329
Structure-activity relationships; aldose reductase inhibitors, 446
Subarachnoid hemorrhage; therapy, 35
Sucralfate
 interactions; naproxen, food, availability, 773
 ulcers; duodenal, therapy, 463
Sulbactam; combination, ampicillin; adnexitis therapy, 275
Sulbactam sodium; combination, ampicillin sodium; i.v., liver abscess therapy, 939
Sulfapyrazole; coronary disease; therapy, 118
Sulfonamides
 National Institute of Allergy and Infectious Diseases; dideoxynosine therapy, pancreatitis risk, AIDS, 832
 olsalazine sodium; FDA approval, ulcerative colitis therapy, 908
 otitis media; therapy, 15
Sustained-action medications; theophylline anhydrous; pharmacokinetics, models, switch from i.v., 458
Sympatholytic agents
 alpha blockers; hypertension therapy, left ventricular heart enlargement, 876
 beta blockers; and nifedipine, silent myocardial ischemia, therapy, 339; congestive heart failure therapy, 853; hypertension therapy, diabetes mellitus, 864; hypertension therapy, left ventricular

heart enlargement, 876
 clonidine; therapy, cyclosporine nephrotoxicity, 49
 isoproterenol hydrochloride; interactions, theophylline-methylprednisolone, potentiation, blood levels, 54

T

Tachycardia; adenosine; paroxysmal supraventricular, therapy, 261, 79
Tamoxifen; breast neoplasms; adjuvant therapy, 667
Tests, laboratory
 nitrogen; urine urea determinations, modified procedures, 371
 quinidine; blood levels, sample collection tubes, 292
Tetracycline; Lyme disease; therapy, 192
Tetracycline hydrochloride; interactions; theophylline, 546
Tetracyclines
 tetracycline; Lyme disease therapy, 192
 tetracycline hydrochloride; interactions, theophylline, 546
Theophylline
 blood levels; aminophylline-isoproterenol-methylprednisolone interactions, potentiation, 54; predictions, i.v. to oral switch, 458; toxicity, predictions, 788
 interactions; tetracycline, 546; toxicity predictions, methodology, 136
 metabolism; congestive heart failure, 936
 National Institute of Allergy and Infectious Diseases; dideoxynosine therapy, pancreatitis risk, AIDS, 832
Theophylline anhydrous; pharmacokinetics; models, switch from i.v., 458
Therapy Consultation, 90, 419
 Use of intravenous infusions in infants and children, 90
 Timing iron dextran doses when plasmapheresis is required, 419
Thrombolytic agents
 alteplase, comparison, streptokinase; alone and with heparin, myocardial infarction, 329
 anistreplase; myocardial infarction therapy, FDA marketing approval, 78
 anistreplase; myocardial infarction, 530
 mucocutaneous lymph node syndrome; therapy, 755
 streptokinase, comparison, alteplase; alone and with heparin, myocardial infarction, 329
Tobramycin; blood levels; gravity flow vs. infusion pumps, 777; minibag vs. syringe pump administration, 541
Topical preparations; metronidazole; rosacea therapy, 94
Toxicity
 see also **Drugs, adverse reactions**
 adenosine; side effects, 261, 271, 79
 aldose reductase inhibitors; side effects, 446
 alteplase, comparison, streptokinase; side effects, myocardial infarction therapy, 329
 amphotericin B; chills, meperidine prophylaxis, 251
 amrinone lactate; DUR criteria, 882
 anistreplase, 78, 530
 anticonvulsants; withdrawal, epilepsy therapy, factors, 781
 anti-infective agents; side effects, 462
 antineoplastic agents; side effects, breast neoplasms adjuvant therapy, 667
 betaxolol hydrochloride; side effects, 87
 carbamazepine; lack, side effects, rectal gels, 13
 clomipramine hydrochloride; side effects, review, 165
 cyclosporine; kidney, transdermal clonidine therapy, 49
 dideoxynosine; pancreatitis, risk, NIAID guidelines, AIDS, 832
 diltiazem; Stevens-Johnson syndrome, 948
 drugs; predictions, blood levels, 788; predictions, methodology, 136
 fat emulsions; medium- and long-chain triglycerides, TPN, 366
 fluconazole; side effects, 231
 fluoxetine hydrochloride; DUR criteria, 955
 ganciclovir; DUR criteria, 644
 gastrointestinal drugs; side effects, diabetic gastroparesis therapy, 357
 globulin immune; i.v., side effects, 489; side effects, 509
 hypotensive agents; side effects, diabetes mellitus, 864

ifosfamide; side effects, 179
 injections; i.v. extravasation, prediction, inline i.v. pressure, infants, 286
 ketorolac tromethamine; side effects, review, 921
 levamisole hydrochloride; side effects, 668
 meperidine hydrochloride; seizures, pediatrics, 337; side effects, patient-controlled analgesia, 92
 mesna; side effects, 179
 moricizine hydrochloride; side effects, 668, 842
 nafarelin acetate; side effects, 318
 nortriptyline hydrochloride; black tongue, 421
 olsalazine sodium; side effects, ulcerative colitis therapy, 908
 pegademase bovine, 408
 penicillamine; side effects, hepatolenticular degeneration therapy, 951
 plantago seed; postcholecystectomy diarrhea therapy, 206
 psychotherapeutic agents; attention deficit disorder therapy, pediatrics, 632
 rifampin; fever, 57
 streptokinase, comparison, alteplase; side effects, myocardial infarction therapy, 329
 theophylline; interactions, tetracycline, 546
 tryptophan; eosinophilia-myalgia syndrome, 250
 vancomycin; DUR criteria, 718
 vancomycin hydrochloride; red-neck syndrome, administration routes, 671
 zidovudine; carcinogenicity, animals, AIDS therapy, 79; side effects, dosage, AIDS therapy, 161
Tranquilizers; clozapine; schizophrenia therapy, 682
Transplantation
 bone marrow; cyclosporine nephrotoxicity, clonidine therapy, 49
 renal; cytomegalovirus immune globulin, market-

ing approval, 493
Triglycerides; fat emulsions; medium and long chains, TPN, 366
Tryptophan; toxicity; eosinophilia-myalgia syndrome, 250
t-PA, see **Alteplase**
Tubes; collection; effects, quinidine blood levels, 292

U

Ulcers; gastrointestinal drugs; duodenal, therapy, 463
Urea; excretion; urine nitrogen determinations, modified procedures, 371
Uremia; therapy; hemorrhage, 673
Urine levels
 nitrogen; urea determinations, modified procedures, 371
 theophylline; congestive heart failure, 936

V

Vaccines
Haemophilus b oligosaccharide conjugate; immunization, infants, age, FDA approvals, 903
 biotechnology; research, FDA applications, 408
Vancomycin
 blood levels; toxicity, predictions, 788
 intravenous; DUR, criteria, quality assurance programs, 718
 peritonitis; therapy, CAPD, 102
Vancomycin hydrochloride

pharmacokinetics; dosage, pediatrics, ECMO, 711
 toxicity; red-neck syndrome, administration routes, 671

Vehicles

alcohols, ethyl; carbamazepine rectal gels, 13
 methylhydroxyethylcellulose; carbamazepine rectal gels, 13

Vitamins; diet; RDA changes, 11

Volume of distribution, see **Drugs**, body distribution

W

Withdrawal, see **Drug withdrawal**

Warfarin sodium; interactions; Osmolite, prothrombin time effects, dosage schedules, 93

Weight; patients; obese, globulin immune, dosage calculations, 909

Z

Zidovudine

acquired immunodeficiency syndrome; dosage, reduction, 161
 carcinogenicity; animals, AIDS therapy, 79
 HIV infections; early treatment, FDA approvals, 248; therapy, pediatrics, 502

Zinc sulfate; hepatolenticular degeneration; low dose therapy, mechanism of action, 951

Author Index

A

- Abobo, Cyril V. see Zenon, Golden J. III, 446
 American Pain Society Principles of analgesic use in the treatment of acute pain and chronic cancer pain, 2nd edition, 601
 Appelman, Maria D. see Okamoto, Mark P., 708
 ASHP Commission on Therapeutics ASHP therapeutic guidelines on nonsurgical antimicrobial prophylaxis, 423
 Atkinson, Ralph C. see Taylor, Jerry W., 948
 Austin, Linda S. see Peters, Mark D. II, 165

B

- Bachmann, Kenneth A. see Sullivan, Timothy J., 136
 Baillie, George R. Red-neck syndrome associated with intraperitoneal vancomycin (letter), 671
 Ball, Daniel W. see Zenon, Golden J. III, 446
 Barone, Joseph A. Book review, 227
 Barr, Judith T. see Schumacher, Gerald E., 788
 Barriere, Steven L. Preventing infectious diseases (editorial), 462
 Barriere, Steven L. see also Killilea, Terrance A., 839
 Baumann, Terry J. Place of ketorolac in pain management (editorial), 938
 Beckett, Brian E. see Spruill, William J., 371
 Berchou, Richard C. Book review, 736
 Berk, Steven I. see Schrader, Bruce J., 118
 Berne, Thomas V. see Okamoto, Mark P., 708
 Bertch, Karen E. Book review, 961
 Bissonnette, Bernard see Lafontaine, Diane, 773
 Bivins, Patricia A. see Hutton, Jimmi, 366
 Bleske, Barry E. Current concepts of silent myocardial ischemia, 339
 Bolam, David L. see Hoie, Eric B., 711
 Bosch, Duane E. Comparison of serum aminoglycoside concentrations produced by two infusion methods, 777
 Bostrom, Alan see Sambol, Nancy C., 873
 Brouard, Agnes Rectal administration of carbamazepine gel (letter), 13
 Brown, Cheryl K. Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis, 357
 Brown, James F. see Kehoe, William A., 458
 Burnett, Richard J. Meperidine for prevention of amphotericin B-induced chills (letter), 252
 Burns, Pamela Criteria for use of amrinone lactate in hospitalized adult patients, 882
 Bussey, Mary E. see Hoie, Eric B., 711

C

- Cadle, Richard M. see Zenon, Golden J. III, 939
 Calis, Karim A. Attention-deficit hyperactivity disorder, 632
 Carter, Barry L. see Zenon, Golden J. III, 446
 Chapman, Stanley W. see Nolan, Rathel L., 57
 Chin, Alfred see Okamoto, Mark P., 708
 Cleary, John D. see Nolan, Rathel L., 57
 Cleary, John D. see also Taylor, Jerry W., 948
 Cochran, Emily B. see Phelps, Stephanie J., 286
 Colburn, Pamela A. see Knapp, Margaret J., 509
 Couch, Patricia Management of uremic bleeding, 673
 Crawford, Keith W. see Strommen, Gordon L., 206
 Cunha, Burke A. Antimicrobial treatment of pelvic inflammatory disease (letter), 840
 Cunha, Burke A. Treatment of pelvic inflammatory disease, 275

D

- Dana, William J. see Schoenike, Steve E., 179
 Davis, Sharon K. see Peters, Mark D. II, 165
 Deeter, Robert G. see Horton, Michael W., 102
 Deeter, Robert G. see also Lisby-Sutch, Susan M., 15
 Diezel-Evans, Lisa M. She died in pain, 612
 DiPiro, Joseph T. see Yee, Gary C., 657
 Dorworth, Thomas E. see Strommen, Gordon L., 206

E

- Edwards, Deborah L. see Nakashima, Lynne, 755
 Eisele, George see Baillie, George R., 671
 Elia, Josephine see Calis, Karim A., 632
 Ereshefsky, Larry Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics, 682

F

- Flint, Nora see Lin, Anne, 718
 Fontan, Jean Eudes see Brouard, Agnes, 13
 Forni, Peter Error in *Cancer Chemotherapy Protocols* (letter), 14
 Forrence, Elizabeth A. see Munger, Mark A., 530
 Friedman, Eitan see Vitiello, Benedetto, 421
 Frisalone, Julie Criteria for use of ciprofloxacin for infections in adult patients, 797
 Fukuchi, Hiroshi Association between dosage and serum concentration of antidepressants, 45

G

- Gaur, Sunanda M. see Lisby-Sutch, Susan M., 15
 Gill, Mark A. see Okamoto, Mark P., 708
 Glazer, Howard M. Book review, 146
 Goodrich, Paul D. see Hoie, Eric B., 711
 Goodwin, S. Diane Management of Lyme disease, 192
 Grabenstein, John D. Book review, 898
 Grebenau, Mark D. Considerations in the use of intravenous immune globulin products (letter), 909
 Griffith, James A. Isoproterenol-theophylline interaction: possible potentiation by other drugs, 54
 Grothe, Dale R. Supersensitivity to subcutaneous lidocaine (letter), 338
 Grothe, Dale R. see also Calis, Karim A., 632

H

- Hamill, Richard J. see Zenon, Golden J. III, 939
 Handsfield, H. Hunter Antimicrobial treatment of pelvic inflammatory disease (letter), 840
 Harris, Patricia see Grothe, Dale R., 338
 Hatton, Jimmi Safety and efficacy of a lipid emulsion containing medium-chain triglycerides, 366
 Healy, Dan see Lin, Anne, 718
 Heseltine, Peter N. R. see Okamoto, Mark P., 708
 Hildebrand, Amy see Barone, Joseph A., 227
 Hoie, Eric B. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation, 711
 Horiuchi, Yasuo see Ueno, Kazuyuki, 936
 Horner, Terry G. see Welty, Timothy E., 35
 Horton, Michael W. Treatment of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis, 102

I

- Ignoffo, Robert J. see Forni, Peter, 14
 Iskenderian, Christy Antimicrobial treatment of pelvic inflammatory disease (letter), 839

J

- Jenck, Mary Ann Anticonvulsant drug withdrawal in seizure-free patients, 781
 Johnson, Mark see Lin, Anne, 718
 Joseph, Jutta C. Management of hypertension in the diabetic patient, 864

K

- Kasperek, Marcia Considerations in the use of intravenous immune globulin products (letter), 909

- Kawaguchi, Yoshihiro see Ueno, Kazuyuki, 936
 Kehoe, William A. First-order versus zero-order absorption models for predicting theophylline concentrations after conversion from intravenous to oral therapy, 458
 Khanderia, Ujjaini see Brown, Cheryl K., 357
 Killilea, Terrance A. Antimicrobial treatment of pelvic inflammatory disease (letter), 839
 Kimura, Masahiko see Fukuchi, Hiroshi, 45
 Kimura, Yasuhiro see Fukuchi, Hiroshi, 45
 Kirkwood, Craig see Lin, Anne, 718
 Kitaura, Teruaki see Fukuchi, Hiroshi, 45
 Knapp, Margaret J. Clinical uses of intravenous immune globulin, 509
 Knowles, Michael R. see Pleasants, Roy A., 541
 Kowalsky, Steven F. see Baillie, George R., 671
 Koyama, Michiko see Ueno, Kazuyuki, 936
 Kozloski, Gary D. see Griffith, James A., 54
 Krenzelok, Edward P. Book review, 659
 Krukemyer, Julie J. Use of β -adrenergic blocking agents in congestive heart failure, 853
 Kyff, Jeffrey V. Meperidine-associated seizures in a child (letter), 337

L

- Lafin, Susan M. see Barone, Joseph A., 227
 Lafleur, Colette M. see Zenk, Karin E., 164
 Lafontaine, Diane Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen, 773
 Lambert, Chantal see Lafontaine, Diane, 773
 Lawson, Lindsay M. see McCormack, James P., 546
 LeBlanc, Kevin L. see Woster, Patricia S., 762
 LeMaistre, Charles F. see Luke, Jacqueline, 49
 Leuschen, M. Patricia Fentanyl excretion in breast milk (letter), 336
 Leuschen, M. Patricia see also Hoie, Eric B., 711
 Lin, Anne Criteria for use of intravenous vancomycin for treatment of infections, 718
 Lisby-Sutch, Susan M. Therapy of otitis media, 15
 Litvak, Kathy M. Ketorolac, an injectable nonnarcotic analgesic, 921
 Lopez, Larry M. Treatment of hypertension: is reduction of blood pressure enough? 876
 Luke, David R. see Luke, Jacqueline, 49
 Luke, Jacqueline Prevention of cyclosporine-induced nephrotoxicity with transdermal clonidine, 49

M

- Maddox, Ray R. Book review, 313
 Mailhot, Claude see Lafontaine, Diane, 773
 Mann, Henry J. Moricizine: a new Class I antiarrhythmic, 842
 Martinez, Rick see Grothe, Dale R., 338
 Masselin, Sylviane see Brouard, Agnes, 13
 Mauro, Laurie Slack Effect of serum separator tubes on serum quinidine concentration measurements, 292
 Mauro, Vincent F. see Mauro, Laurie Slack, 292
 Mayet, Iqbal Y. Low-dose zinc therapy for maintenance treatment of Wilson's disease, 951
 McCollam, Patrick L. see Parker, Robert B., 261
 McCormack, James P. Theophylline toxicity induced by tetracycline, 546
 McCue, Anne B. Amikacin pharmacokinetics in a patient with spinal cord injury (letter), 163
 McEvoy, Gerald K. see Litvak, Kathy M., 921
 McEvoy, Gerald K. see also Schmadel, Linda A., 94
 Miller, Jane L. Conference examines study-design issues in AIDS research (News), 153
 Miller, Lucinda G. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations, 125
 Miyai, Kazuyoshi see Ueno, Kazuyuki, 936
 Miyake, Katsushi see Fukuchi, Hiroshi, 45
 Mowers, Robert M. see Siepler, John K., 463
 Munger, Mark A. Anistreplase: a new thrombolytic for the treatment of acute myocardial infarction, 530

N

- Nahata, Milap C. Discovery of the gene defect in cystic fibrosis: implications for diagnosis and treatment,

716

Nakahara, Toshio see Fukuchi, Hiroshi, 45
 Nakashima, Lynne Treatment of Kawasaki disease, 755

Nelson, Robert M. Jr. see Hoie, Eric B., 711
 Nemec-Dwyer, Mary A. see Lisby-Sutch, Susan M., 15
 Nolan, Rathel L. Fever associated with daily rifampin therapy, 57

O

Okamoto, Mark P. Comparison of two microcomputer Bayesian pharmacokinetic programs for predicting serum gentamicin concentrations, 708
 Oldfield, Edward C. III Meperidine for prevention of amphotericin B-induced chills (letter), 251
 Ondrejicka, John S. see Burns, Pamela, 882
 Ostrosky, John see Frisalone, Julie, 797
 Ostrosky, John see also Lin, Anne, 718
 Ott, Linda G. see Hatton, Jimmi, 366

P

Parker, Robert B. Adenosine in the episodic treatment of paroxysmal supraventricular tachycardia, 261
 Paryani, Sharon G. see Renfro, William H., 550
 Pau, Alice K. Management of cytomegalovirus infection in patients with acquired immunodeficiency syndrome, 613
 Peters, Mark D. II Clomipramine: an antiobsessional tricyclic antidepressant, 165
 Petretich, Deborah A. Reversal of Osmolite-warfarin interaction by changing warfarin administration time (letter), 93
 Phelps, Stephanie J. Inability of inline pressure monitoring to predict or detect infiltration of peripheral intravenous catheters in infants, 286
 Pilla, Alison M. see Zarowitz, Barbara J., 40
 Pittrak, David L. see Pau, Alice K., 613
 Pitterle, Michael Treatment of attention-deficit hyperactivity disorder (editorial), 643
 Pleasants, Roy A. Influence of infusion method on serum tobramycin concentrations in adults with cystic fibrosis, 541
 Popovich, John Jr. see Zarowitz, Barbara J., 40
 Porter, R. Stephen Adenosine: supplementary considerations about activity and use, 271
 Pucino, Frank see Strommen, Gordon L., 206

R

Rapp, Robert P. see Hatton, Jimmi, 366
 Rayburn, William F. see Leuschen, M. Patricia, 336
 Record, Kenneth E. see Hatton, Jimmi, 366
 Reents, Stan B. see Burnett, Richard J., 252
 Reid, Stewart E. see McCormack, James P., 546
 Renfro, William H. Criteria for use of immune globulin (IVIG), 550
 Reynolds, Maryann S. see Jenck, Mary Ann, 781

Rice, Ted L. see Kyff, Jeffrey V., 337
 Rowan, Ann see Spruill, William J., 371
 Russell, Wayne L. see Goodwin, S. Diane, 192

S

Sambol, Nancy C. Effect of hydrochlorothiazide 25 mg/day on essential hypertension, 873
 Sarai, Keisuke see Fukuchi, Hiroshi, 45
 Savitsky, Patricia A. Criteria for use of fluoxetine hydrochloride in adult inpatients and outpatients, 955
 Schadt, Randy F. see Smythe, Maureen A., 92
 Schmadel, Linda K. Topical metronidazole: a new therapy for rosacea, 94
 Schell, Kenneth H. see Zenk, Karin E., 164
 Schoenike, Steve E. Ifosfamide and mesna, 179
 Schrader, Bruce J. Antiplatelet agents in coronary artery disease, 118
 Schumacher, Gerald E. Using population-based serum drug concentration cutoff values to predict toxicity: test performance and limitations compared with Bayesian interpretation, 788
 Schuna, Arthur A. see Joseph, Jutta C., 864
 Seki, Takeshi see Ueno, Kazuyuki, 936
 Shea, Michael J. see Bleske, Barry E., 339
 Sherman, Richard A. see Horton, Michael W., 102
 Siepler, John K. Selecting drug therapy for patients with duodenal ulcers, 463
 Smythe, Maureen A. Patient-controlled analgesia with meperidine after cesarean section (letter), 92
 Sproat, Thomas T. see Goodwin, S. Diane, 192
 Spruill, William J. Determination of urinary urea nitrogen concentration with modified blood urea nitrogen procedures, 371
 Spruill, William J. Timing iron dextran doses when plasmapheresis is required (Therapy Consultation), 419
 Strommen, Gordon L. Treatment of suspected postcholecystectomy diarrhea with psyllium hydrophilic mucilloid, 206
 Stumpf, Janice L. see Couch, Patricia, 673
 Sullivan, Timothy J. Method for assessing the probability of toxicity from drug interactions having a pharmacokinetic basis, 136
 Sunderland, Trey see Grothe, Dale R., 338
 Swigart, Scott A. see Hoie, Eric B., 711
 Symes, Laura see Frisalone, Julie, 797

T

Tan, Paul see McCue, Anne B., 163
 Tartaglione, Teresa A. see Handsfield, H. Hunter, 840
 Taylor, Jerry W. Stevens-Johnson syndrome associated with diltiazem, 948
 Terrier, Jean Loup see Brouard, Agnes, 13
 Todd, Mark W. Criteria for use of ganciclovir in adult and pediatric patients, 644
 Tolley, Elizabeth A. see Phelps, Stephanie J., 286
 Tran-Johnson, Tram K. see Ereshefsky, Larry, 682
 Trudeau, Walter L. see Siepler, John K., 463
 Twyman, Diana see Hatton, Jimmi, 366

U

Ueno, Kazuyuki Effect of congestive heart failure on theophylline disposition, 936

V

Vermeulen, Michel see Lafontaine, Diane, 773
 Vitiello, Benedetto Plasma and salivary nortriptyline concentrations in a patient with black tongue (letter), 421
 Vitiello, Benedetto see also Grothe, Dale R., 338

W

Wade, William E. see Spruill, William J., 371
 Walker, Paul R. see Strommen, Gordon L., 206
 Waltner, William E. see Pleasants, Roy A., 541
 Watanabe, Mark D. see Ereshefsky, Larry, 682
 Welty, Timothy E. Pathophysiology and treatment of subarachnoid hemorrhage, 35
 Wetmore, Robert see Kasperek, Marcia, 909
 Willett, Lynne D. see Hoie, Eric B., 711
 Williams, David N. see Bosch, Duane E., 777
 Williams, Dennis M. Book review, 226
 Williams, Dennis M. see also Pleasants, Roy A., 541
 Williams, Loretta A. see Luke, Jacqueline, 49
 Williams, Paul J. see Kehoe, William A., 458
 Williams, Roger L. see Sambol, Nancy C., 873
 Wolf, Lynda J. see Leuschen, M. Patricia, 336
 Wong, Robbie Scientific perspectives from the Sixth International Conference on AIDS (News), 743
 Woster, Patricia S. Management of elevated intracranial pressure, 762

Y

Yau, Jonathan C. see Luke, Jacqueline, 49
 Yee, Gary C. Book review, 657
 Yellin, Albert E. see Okamoto, Mark P., 708
 Yeung, Jupiter see Vitiello, Benedetto, 421

Z

Zarowitz, Barbara J. Expanded gentamicin volume of distribution in patients with indicators of malnutrition, 40
 Zenk, Karin E. Need for pediatric data in review articles (letter), 164
 Zenk, Karin E. Use of intraosseous infusions in infants and children (Therapy Consultation), 90
 Zenon, Golden J. III Ampicillin-sulbactam in the treatment of multiple pyogenic liver abscesses, 939
 Zenon, Golden J. III Potential use of aldose reductase inhibitors to prevent diabetic complications, 446